I agree that this site is using cookies. You can find further informations here.
X
Kazandjian, Dickran
92  results:
Search for persons X
?
1

Minimal Residual Disease-Adapted Therapy in Multiple Myelom..:

Meseha, Mina ; Hoffman, James ; Kazandjian, Dickran..
Current Oncology Reports.  26 (2024)  6 - p. 679-690 , 2024
Link: https://doi.org/10.1007/..
 
?
2

EVIDENCE meta-analysis: evaluating minimal residual disease..:

Landgren, Ola ; Prior, Thomas J ; Masterson, Tara...
Blood Journal.  , 2024
Link: https://doi.org/10.1182/..
 
?
3

Extreme body mass index and survival in newly diagnosed mul..:

Shah, Urvi A. ; Whiting, Karissa ; Devlin, Sean...
Blood Cancer Journal.  13 (2023)  1 - p. , 2023
Link: https://doi.org/10.1038/..
 
?
4

Genomic and immune signatures predict clinical outcome in n..:

Maura, Francesco ; Boyle, Eileen M. ; Coffey, David...
Nature Cancer.  4 (2023)  12 - p. 1660-1674 , 2023
Link: https://doi.org/10.1038/..
 
?
5

P-342 Genomic profiling of treated high-risk smoldering mul..:

Diamond, Benjamin ; Kazandjian, Dickran ; Papadimitriou, Marios...
Clinical Lymphoma Myeloma and Leukemia.  23 (2023)  - p. S227-S228 , 2023
Link: https://doi.org/10.1016/..
 
?
6

Immunophenotypic correlates of sustained MRD negativity in ..:

Coffey, David G. ; Maura, Francesco ; Gonzalez-Kozlova, Edgar...
Nature Communications.  14 (2023)  1 - p. , 2023
Link: https://doi.org/10.1038/..
 
?
7

POSTER: AML-396 Blastic Plasmacytoid Dendritic Cell Neoplas..:

Voskanyan, Astghik ; Badikyan, Maria ; Konopleva, Marina...
Clinical Lymphoma Myeloma and Leukemia.  23 (2023)  - p. S161 , 2023
Link: https://doi.org/10.1016/..
 
?
8

AML-396 Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN..:

Voskanyan, Astghik ; Badikyan, Maria ; Konopleva, Marina...
Clinical Lymphoma Myeloma and Leukemia.  23 (2023)  - p. S296-S297 , 2023
Link: https://doi.org/10.1016/..
 
?
9

Publisher Correction: Oncogenic RAS commandeers amino acid ..:

Yang, Yandan ; Bolomsky, Arnold ; Oellerich, Thomas...
Nature Communications.  13 (2022)  1 - p. , 2022
Link: https://doi.org/10.1038/..
 
?
10

P-136: Global myeloma trial participation and drug access i..:

Fatoki, Raleigh ; Koehn, Kelly ; Kelkar, Amar...
Clinical Lymphoma Myeloma and Leukemia.  22 (2022)  - p. S110 , 2022
Link: https://doi.org/10.1016/..
 
?
11

Combination venetoclax and selinexor effective in relapsed ..:

Nguyen, Nina ; Chaudhry, Sana ; Totiger, Tulasigeri M....
npj Precision Oncology.  6 (2022)  1 - p. , 2022
Link: https://doi.org/10.1038/..
 
?
12

Oncogenic RAS commandeers amino acid sensing machinery to a..:

Yang, Yandan ; Bolomsky, Arnold ; Oellerich, Thomas...
Nature Communications.  13 (2022)  1 - p. , 2022
Link: https://doi.org/10.1038/..
 
?
13

P-047: ADVANCE multicenter clinical trial: MRD-driven thera..:

Landgren, Ola ; Maura, Francesco ; Kazandjian, Dickran
Clinical Lymphoma Myeloma and Leukemia.  22 (2022)  - p. S61 , 2022
Link: https://doi.org/10.1016/..
 
?
14

Monoclonal gammopathies of clinical significance (MGCS): In..:

Oganesyan, Artem ; Gregory, Andrew ; Malard, Florent...
Frontiers in Immunology.  13 (2022)  - p. , 2022
Link: https://doi.org/10.3389/..
 
?
15

Avelumab, a PD-L1 Inhibitor, in Combination with Hypofracti..:

Kazandjian, Dickran ; Dew, Alexander ; Hill, Elizabeth...
The Oncologist.  26 (2021)  4 - p. 288-e541 , 2021
Link: https://doi.org/10.1002/..
 
1-15